RxDoctor Payments Data

Kylee Graef, PA

Physician Assistant · Meridian, IDNPI 1538679840

Payments from drug & device makers

$1,702in general payments, 2019–2025

Across 34 payments — averaging $50.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$349
  • Abbott$282
  • Tandem Diabetes Care, Inc.$201
  • AstraZeneca$191
  • Dexcom, Inc.$174
  • Amgen$129
  • plus $376 from 5 others

What the payments were for

  • Food & beverage$1,67098%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,702 in reported general payments places this provider in the 80th percentile of 1,027 physician assistant providers in Idaho.

See all physician assistant providers in Idaho

Medicare billing

Part B allowed, 2024
$14,544
Medicare patients
89
Services billed
218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide130$186,512
MounjaroTirzepatide128$161,242
JardianceEmpagliflozin56$76,018
TrulicityDulaglutide32$49,286
FarxigaDapagliflozin Propanediol29$30,979
RybelsusSemaglutide11$25,593
Tresiba Flextouch U-200Insulin Degludec17$25,014
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$23,926
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/721$16,572
Lantus SolostarInsulin Glargine,hum.Rec.Anlog112$14,984
Novolog FlexpenInsulin Aspart49$13,453
JanuviaSitagliptin Phosphate15$12,889
Insulin Lispro Kwikpen U-100Insulin Lispro34$12,101
Gvoke Hypopen 2-PackGlucagon17$11,871
Tresiba Flextouch U-100Insulin Degludec22$11,866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog$18$222,148197 claims
Novo NordiskOzempic, Rybelsus$111$212,106141 claims
AstraZenecaFarxiga$191$30,97929 claims
Sanofi-aventis U.S. LLCLantus$99$1,19411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,027 physician assistant providers in Idaho.

Other physician assistant in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →